Previous 10 | Next 10 |
10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022 PR Newswire PLEASANTON, Calif. , Jan. 26, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter ...
10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network Q2 Solutions, Azenta Life Sciences, and CellCarta to support large-scale clinical research trials for global pharmaceutical partners PR Newswire PLEASANTON, Cali...
10x Genomics to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire PLEASANTON, Calif. , Dec. 22, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the company will be participating in the upcoming 40th Annual J....
This is the second part of my update on the holdings in my portfolios. A strong group of long-horizon companies and turnaround plays, best suited for risk-averse investors, especially at current valuations. In the articles, I deep dive my thesis on most of these names, so feel fre...
A large number of names in ARKK are also in the manager's other themed funds, which have their set of risks. Underperformance in the YTD is largely attributable to lack of diversification and proprietary weighing strategy. "Cross-holding" with other funds potentially should b...
Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...
10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year Award for Chromium X is the latest example of the company's track record of breakthrough technologies pushing life science research forward PR Newswire PLEASANTON, Calif. ...
The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Like the internet revolution, companies that enable or effectively harness synthetic...
Despite crushing the S&P 500 -- 180% to 63% -- since its September 2019 IPO, 10x Genomics ' (NASDAQ: TXG) shares have only experienced 6% growth year to date. The company has rapidly become a cornerstone of biomedical research with its laboratory devices capable of profi...
If you are looking to invest in companies that aim to provide disruptive technology to the healthcare sector, there can be plenty of intriguing options. While some of those may lack a solid foundation to build a high-quality business on, 10x Genomics (NASDAQ: TXG) and DermTech ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...